The Science of Psychedelics for Mental Health
Summary
Dr. Robin Carhart-Harris, a leading psychedelics researcher at UCSF, discusses how classic psychedelics like psilocybin, LSD, and DMT alter brain connectivity and how these changes relate to therapeutic outcomes in depression, PTSD, and other psychiatric conditions. The conversation covers clinical trial results, the mechanics of the psychedelic experience, neuroplasticity, and the ongoing debate around microdosing versus macrodosing.
Key Takeaways
- Psilocybin therapy achieved ~70% response rates for major depression in clinical trials, far exceeding typical antidepressant outcomes
- The subjective experience matters therapeutically — the magnitude of the psychedelic journey reliably predicts therapeutic outcomes across independent studies
- Increased cross-modular brain connectivity observed during a psychedelic session persists the next day and up to three weeks later, correlating with depression symptom improvement
- Microdosing evidence is weak: a well-designed placebo-controlled study found that the placebo response (driven by expectancy) explained most of the reported benefits
- The therapeutic triad of “trust, let go, be open” is a core principle in psychedelic therapy, with therapeutic rapport measurably predicting experience quality and outcomes
- Music is a staple component of all major published psychedelic therapy trials and may synergize with the drug to amplify emotional processing
- Integration after the session — through therapy, journaling, meditation, or mindfulness practice — is essential and may need to continue long-term as an ongoing practice
- Psilocybin therapy is showing early promising results for anorexia nervosa, one of the deadliest psychiatric illnesses
- Non-hallucinogenic psychedelic analogs being developed by biotech companies are viewed skeptically, as the cathartic, psyche-revealing experience may be central to the therapeutic mechanism
Detailed Notes
What Are Psychedelics?
The word psychedelic was coined by British psychiatrist Humphry Osmond in 1956 from two ancient Greek roots:
- Psyche — mind or soul
- Delos — to make visible, to reveal
Osmond coined it as an alternative to psychotomimetic (drugs that mimic psychosis), feeling the term failed to capture the fuller nature of the experience. The term is intentionally valence-neutral — it does not imply a good or bad experience, only that aspects of the mind are revealed.
Pharmacologically, classic psychedelics (psilocybin, LSD, DMT, mescaline) are defined by their action at the serotonin 2A receptor. However, Dr. Carhart-Harris argues the subjective experience cannot be separated from the definition.
Dosage Calibration: Psilocybin
- Rough conversion: ~1% of dried mushroom mass is psilocybin/psilocin, so 1 gram of mushrooms ≈ 10 mg of psilocybin
- Clinical trial doses:
- 25 mg psilocybin — full macrodose, produces strong psychedelic effects
- 10 mg psilocybin — moderate dose
- 1 mg psilocybin — functionally a placebo; no measurable brain changes on EEG
- LSD microdose threshold: approximately 10–12 micrograms (sub-perceptual for most people)
Microdosing: What the Evidence Actually Shows
- Microdosing involves taking sub-perceptual doses of a psychedelic (e.g., LSD or psilocybin) on a schedule such as every other day or every third day
- Current evidence is weak — no compelling placebo-controlled data supports cognitive or mood benefits
- A creative citizen science study (Szigeti et al., Imperial College) had participants blind their own LSD microdoses using opaque capsules and QR codes
- Result: Placebo performed as well as the active microdose
- The effect was largely driven by positive expectancy, not the drug itself
- A pending New Zealand randomized controlled trial shows preliminary improvements in mood but has not yet been peer-reviewed
The Psychedelic Journey: Phases and Therapeutic Mechanisms
Set and setting in clinical trials:
- Patients lie on a sofa or bed, wearing eye masks
- Two therapists present throughout (ideally licensed mental health professionals)
- Music played throughout — starting spacious and building in emotional intensity; no lyrics initially
Phases of the experience (based on research by Harry Brouwer):
- Early phase: dominated by anxiety, disorientation, fear of death or loss of sanity — described as a basic drug action of ego dissolution
- Later phase: emotional release, insight, positive affect, and often catharsis
Key therapeutic principle — “Trust, Let Go, Be Open”:
- Attributed to psychedelic therapy pioneer Bill Richards
- Trust: Therapeutic rapport measured the morning of dosing predicts experience quality and outcomes weeks later
- Let go: Measured willingness to surrender predicts therapeutic response
- Be open: Willingness to confront difficult material, including trauma
Brain Mechanisms: Connectivity and Neuroplasticity
During the psychedelic session:
- Classic psychedelics produce a dramatic increase in global functional connectivity — brain regions that normally communicate within their own module begin communicating across modules
- This decrease in modularity correlates with the intensity of subjective effects
- Replicated across psilocybin, LSD, and DMT using fMRI
After the session:
- Residual increased connectivity observed the next day in depression cohorts
- Still present at three weeks in a subsequent independent study
- The magnitude of connectivity change correlates with symptom improvement in depression
Structural brain changes (new unpublished data from healthy volunteers study):
- Using diffusion tensor imaging (white matter tract analysis), anatomical changes were found in major fiber tracts connecting:
- Prefrontal cortex ↔ Thalamus
- Prefrontal cortex ↔ Striatum
- These structural changes were seen only with 25 mg psilocybin, not placebo
The Entropic Brain Effect:
- EEG recordings show psilocybin increases the informational complexity of brain activity — patterns become less predictable and more informationally rich
- Scales with subjective intensity of the experience
Psychedelic Therapy vs. SSRI Pharmacotherapy
In a landmark study published in the New England Journal of Medicine, psilocybin therapy was compared to escitalopram (Lexapro):
- Psilocybin: two sessions of 25 mg, three weeks apart
- Escitalopram: six weeks of daily dosing plus 1 mg psilocybin (functional placebo)
- Psychotherapy standardized across both arms
- Psilocybin therapy showed superior results on several measures
Key conceptual distinction:
- SSRIs = “sit on” emotions (chronic suppression)
- Psychedelic therapy = “sit with” emotions (processing and integration)
Integration: What Happens After the Session
- Integration refers to consolidating insights and changes from the psychedelic experience into lasting behavioral and psychological shifts
- The therapeutic team typically supports integration in the weeks following dosing
- Long-term integration may require ongoing personal practice analogous to meditation
- Mindfulness and meditation are seen as important complements — training the capacity to observe difficult internal states without reactivity
- The concept of a “psychedelic practice” (like a meditation practice) is emerging as a framework for sustained benefit
Applications Beyond Depression
- PTSD: MDMA-assisted therapy (not a classic psychedelic but often grouped alongside) enables patients to approach trauma with reduced fear response
- Anorexia nervosa: Ongoing psilocybin trial (3 sessions, ~2 weeks apart) showing preliminary improvements in obsessive food-related thinking and weight at follow-up — significant given anorexia’s status as the deadliest psychiatric illness
- Healthy individuals: Psilocybin (25 mg) in psychedelic-naive middle-aged subjects showed significant improvements in psychological well-being